Ian W. Flinn

54.2k citations
542 papers · 18.8k indexed · 8 hit papers · h-index 66
Topics
Chronic Lymphocytic Leukemia Research (369 papers)Lymphoma Diagnosis and Treatment (295 papers)CAR-T cell therapy research (85 papers)

In The Last Decade

Ian W. Flinn

524 papers receiving 18.4k citations

Hit Papers

Therapeutic role of alemtuzumab (Campath-1H) in patients ...200220262010201820022004201620122014200400600

Peers

Ian W. Flinn
Comparison fields: 5 of 114
  • Genetics 11.5k
  • Pathology and Forensic Medicine 10.1k
  • Oncology 6.0k
  • Hematology 5.4k
  • Immunology 4.7k
Replace Alessandra Ferrajoli with:
Alessandra Ferrajoli United States
Emili Montserrat Spain
Hervé Tilly France
Richard R. Furman United States
Stephan Stilgenbauer Germany
Pierre Morel France
Paolo Ghia Italy
Eric D. Hsi United States
Corinne Haïoun France
Anton Hagenbeek Netherlands
Ian W. Flinn relative to Alessandra Ferrajoli United States Alessandra Ferrajoli's profile →
Citations per field
00.5×3.3×
Alessandra Ferrajoli · 1×
Citations per year

Countries citing papers authored by Ian W. Flinn

Since Specialization
Citations

This map shows the geographic impact of Ian W. Flinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian W. Flinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian W. Flinn more than expected).

Fields of papers citing papers by Ian W. Flinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian W. Flinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian W. Flinn. The network helps show where Ian W. Flinn may publish in the future.

Co-authorship network of co-authors of Ian W. Flinn

This figure shows the co-authorship network connecting the top 25 collaborators of Ian W. Flinn. A scholar is included among the top collaborators of Ian W. Flinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian W. Flinn. Ian W. Flinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 2
4 34
5 15
6 15
7 10
8 2
9 22
10 126
11 27
12 20
13 33
14 47
15 183
16 112
17
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studybreakdown →
419
18 256
19 300
20 306

About Ian W. Flinn

Ian W. Flinn is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 542 papers that have together received 18.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (369 papers), Lymphoma Diagnosis and Treatment (295 papers) and CAR-T cell therapy research (85 papers). The work is most often cited by research in Genetics (11.5k citations), Pathology and Forensic Medicine (10.1k citations) and Hematology (5.4k citations). Ian W. Flinn has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include John C. Byrd, Michael R. Grever, Steven Coutré, R. Kanti, Brad S. Kahl, Richard R. Furman, Richard F. Ambinder, Richard A. Larson, Thomas J. Kipps and John C. Byrd. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026